Skip to main content
SpringerLink
Log in

Effect of NIPRISAN® on CYP3A4 activity in vitro

  • Short Communication
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

NIPRISAN® is a phytomedicine developed from herbal products used in folkloric practice for the management of sickle cell disease (SCD). The effect of NIPRISAN® was tested on human cytochrome P4503A4 drug metabolising enzyme to generate clinically significant data for its safe and efficacious use. Inhibitory activity on CYP3A4 was measured with and without the addition of NIPRISAN®, by testing different concentrations of the product at 37 °C in reactive mixtures with ketoconazole (2.5 μM) as the positive control. Results showed a low IC50 value of 0.06 mg/ml, indicating that metabolic processes of NIPRISAN® are likely to inhibit CYP3A4. The result suggests possible herb–drug interaction may occur, with potential implication on common medications that are CYP3A4 substrates. It is, therefore, advocated that concomitant administration of NIPRISAN® along with medications that are CYP3A4 substrates should be done with caution so as not to compromise NIPRISAN®’s established beneficial effect in the management of SCD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  • Adzu B, Garba M, Haruna A, Maman M, Wambebe C, Gamaniel K (2001) Effect of NIPRISAN® on single oral dose pharmacokinetics of paracetamol in rats. Eur J Drug Metab Pharmacokinet 26:201–204

    Article  CAS  PubMed  Google Scholar 

  • Adzu B, Mustapha KB, Masimirembwa C, Obodozie O, Kirim RA, Gamaniel KS (2013) Simulation of metabolism-based herb-drug interaction: towards safe and efficacious use of NIPRD-AM1. Avicenna J Phytomed 3:201–204

    PubMed Central  PubMed  Google Scholar 

  • African Drugs and Diagnostic Network Innovation (ANDI)/United Nations Economic Commission for Africa (UNECA); Research grant for ‘Co-formulation of NIPRISAN with two routine drugs used in the management of sickle cell disease (SCD) in Africa’, August 2012

  • Amidon GL, Lennernas H, Shap VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification-the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–420

    Article  CAS  PubMed  Google Scholar 

  • Awad R, Arnason JT, Trudeau V, Bergeron C, Budzinski JW, Foster BC, Merali Z (2003) Phytochemical and biological analysis of Skullcap (Scutellaria lateriflora L.): A medicinal plant with anxiolytic properties. Phytomedicine 10:640–649

    Article  CAS  PubMed  Google Scholar 

  • Awodogan AO, Wambebe C, Gamaniel K, Okogun JI, Orisadipe AT, Akah PA (1996) Acute and short term toxicity of NIPRISAN in rats. I: a biochemical study. J Pharm Res Dev 1:39–45

    Google Scholar 

  • Bailey DG, Dresser GK (2004) Natural products and adverse drug interaction. Can Med Assoc J 170:1531–1532

    Article  Google Scholar 

  • Bakare-Odunola MT, Mustapha KB, Garba M, Obodozie OO, Enemali IS (2010) The influence of Nifadin, Niprisan and Niprd/92/001/1-1 (AM-1) on pharmacokinetics of metronidazole in rats. Eur J Drug Metab Pharmacokinet 35:55–58

    Article  CAS  PubMed  Google Scholar 

  • Doehmer J, Eisenbraun J (2012) Assessment of extracts from Mistletoe (Viscum album) for herb–drug interaction by inhibition and induction of cytochrome P450 activities. Phytother Res 26:11–17

    Article  CAS  PubMed  Google Scholar 

  • Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491

    Article  CAS  PubMed  Google Scholar 

  • Fugh-Berman A (2000) Herb-drug interactions. Lancet 355:134–138

    Article  CAS  PubMed  Google Scholar 

  • Galetin A, Clarke SE, Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31:1108–1116

    Article  CAS  PubMed  Google Scholar 

  • Gamaniel K, Amos A, Akah PA, Samuel BB, Kapu S, Olusola A, Abayomi O, Okogun JI, Wambebe C (1998) Pharmacological profile of NIPRD 94/002/1-0: a novel herbal antisickling agent. J Pharm Res Dev 3:89–94

    Google Scholar 

  • Gwaza L, Wolfe AR, Benet LZ, Guglielmo BJ, Chagwera TE, Maponga CC, Masimirembwa CM (2009) In vitro inhibitory effects of Hypoxis obtuse and Dicoma anomala on cyp450 enzymes and p-glycoprotein. Afr J Pharm Pharmacol 3:539–546

    Google Scholar 

  • Iyamu EW, Turner EA, Asakura T (2002) In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Br J Haematol 118:337–343

    Article  CAS  PubMed  Google Scholar 

  • Iyamu EW, Turner EA, Asakura T (2003) NIPRISAN (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol 122:1001–1008

    Article  CAS  PubMed  Google Scholar 

  • Lau C, Mooiman KD, Maas-Baker RF, Beijnen JH, Schellens JHM, Meijerman I (2013) Effect of Chinese herbs on CYP3A4 activity and expression in vitro. J Ethnopharmacol 149:543–549

    Article  CAS  PubMed  Google Scholar 

  • Lipinski CA, Lambardo F, Dominy B, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25

    Article  CAS  Google Scholar 

  • Mu H, Holm R, Mũllrtz A (2013) Lipid-based formulations for oral administration of poorly water soluble drugs. Int J Pharmaceutics 453:215–220

    Article  CAS  Google Scholar 

  • Mustapha KB, Bakare-Odunola MT, Garba M, Obodozie OO (2009) Effect of phytomedicine, AM-1, niprisan and nifadin on pharmacokinetics of chloroquine in rats. Eur J Drug Metab Pharmacokinet 34:151–155

    Article  CAS  PubMed  Google Scholar 

  • Nerbert DW, Russell DW (2002) Clinical importance of the cytochromes p450. Lancet 360:1155–1162

    Article  Google Scholar 

  • Obodozie O, Ameh SJ, Afolabi EK, Oyedele EO, Ache TA, Onanuga CE, Ibe MC, Inyang US (2009) Standardization of the components of niprisan: a phytomedicine for treating Sickle Cell Disease. J Med Plants Res 3:284–289

    Google Scholar 

  • Wambebe C, Ogunyale PO, Gamaniel KS, Nasipuri RN, Okogun JI, Samuel B, Olusola A, Orisadipe, A. (1998). Piper guineense, Pterocarpus osun, Eugenia caryophyllata and Sorghum bicolor extracts for treating sickle cell disease. United States Patent No. 5,800,819 of September 1, 1998

  • Pal D, Mitra A (2006) MDR-and CYP3A4-mediated drug-herbal interactions. Life Sci 78:2131–2145

    Article  CAS  PubMed  Google Scholar 

  • Saunthararaj J, Vichinsky EP (2012) Sickle cell disease: clinical features and management. In: Hoffman R, Benz EJ Jr, Sillberstein LE, Heslop HE, Weitz JI (eds) Hematology: basic principles and practice, 6th edn. Saunders Elsevier, Philadelphia Ch. 40

    Google Scholar 

  • Wambebe C (2006) From plants to medicine for management of sickle cell disorder. Guest Editor Innov Discov 18:1–4

    Google Scholar 

  • Wambebe C, Khamofu H, Momoh JAF, Ekpeyong M, Abdu BS, Njoku OS, Bamgboye EA, Nasipuri RN, Kunle OO, Okogun JI, Enwerem MN, Audam JG, Gamaniel KS, Obodozie OO, Samuel B, Fojule G, Ogunyale O (2001a) Double-blind, placebo controlled, randomized cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder. Phytomedicine 8:252–261

    Article  CAS  PubMed  Google Scholar 

  • Wambebe CO, Bamgboye EA, Badru BO, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku SO, Nasipuri NR, Kunle OO, Okogun JI, Enwerem NM, Gamaniel SK, Obodozie OO, Samuel B, Fojule G, Ogunyale PO (2001b) Efficacy of niprisan in the prophylactic management of patients with Sickle Cell Disease. Curr Ther Res 62:26–34

    Article  CAS  Google Scholar 

  • WHO (2000) General guidelines for methodologies on research and evaluation of traditional medicines. World Health Organisations, Geneva WHO/EDM/TRM/2000.1

    Google Scholar 

  • Wienkers LC, Heath TG (2005) Predicting the in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Disc 4:825–833

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors appreciate the technical contribution of Kimberley Smasher.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Toxicology, National Institute for Pharmaceutical Research and Development (NIPRD), PMB 21, Abuja, Nigeria

    Bulus Adzu

  2. African Institute of Biomedical Science and Technology (AiBST), Cnr Chinhoyi Str./Jason Moyo Ave. No. 9 at LAPF Centre, Harare, Zimbabwe

    Collen Masimirembwa & Roslyn Thelingwani

  3. Department of Medicinal Chemistry and Quality Control, NIPRD, PMB 21, Abuja, Nigeria

    Kudirat Bola Mustapha & Rukaiyatu Abdullahi Kirim

  4. Director General/Chief Executive Officer, NIPRD, PMB 21, Abuja, Nigeria

    Karniyus Shingu Gamaniel

Authors
  1. Bulus Adzu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Collen Masimirembwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kudirat Bola Mustapha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roslyn Thelingwani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rukaiyatu Abdullahi Kirim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Karniyus Shingu Gamaniel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bulus Adzu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adzu, B., Masimirembwa, C., Mustapha, K.B. et al. Effect of NIPRISAN® on CYP3A4 activity in vitro. Eur J Drug Metab Pharmacokinet 40, 115–118 (2015). https://doi.org/10.1007/s13318-014-0173-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-014-0173-1

Keywords

Search

Navigation